2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepin-3-one | 195985-91-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepin-3-one
• 英文别名: 2-phenylethyl-2,3,4,5-tetrahydrobenzodiazepin-3-one；1,2,4,5-Tetrahydro-2-(2-phenylethyl)-3H-1,4-benzodiazepin-3-one；2-(2-Phenylethyl)-1,2,4,5-tetrahydro-1,4-benzodiazepin-3-one
• CAS: 195985-91-2
• 化学式: C₁₇H₁₈N₂O
• 分子量: 266.343
• InChiKey: WLQLSLNIPGUFLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepin-3-one 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 4-(4-fluorophenylsulfonyl)-2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepine
  参考文献：
  名称：

  Benzodiazepine-based selective inhibitors of mitochondrial F 1 F 0 ATP hydrolase

  摘要：

  A series of benzodiazepine-based inhibitors of mitochondrial F1F0 ATP hydrolase were prepared and evaluated for their ability to selectively inhibit the enzyme in the forward direction. Compounds from this series showed excellent potency and selectivity for ATP hydrolase versus ATP synthase, suggesting a potentially beneficial profile useful for the treatment of ischemic heart disease. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.052
• 作为产物：
  描述：

  2-氧代-4-苯基丁酸乙酯 在 三乙基硅烷 、 三氟乙酸 、 sodium hydroxide 作用下， 以 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 38.0h， 生成 2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepin-3-one
  参考文献：
  名称：

  [EN] INHIBITORS OF ATP SYNTHASE - COSMETIC AND THERAPEUTIC USES
  [FR] INHIBITEURS D'UTILISATIONS COSMÉTIQUES ET THÉRAPEUTIQUES D'ATP SYNTHASE

  摘要：

  本公开教导了IF1蛋白活性是寿命的分子决定因素，通过支持实验数据解释了不同物种具有不同最大寿命的原因。本公开教导了使用IF1蛋白/片段（或其序列变体）或其融合蛋白作为减缓/延迟/减少受试者衰老的药剂，可选作为化妆品组分，可选用于治疗与年龄相关的疾病/失调。此外，本公开还教导了其他F1F0 ATP水解抑制剂，包括多种不同支架的小分子，用于此目的。此外，通过支持实验数据，本公开还教导了减缓ATP合成酶的ATP水解模式的化合物对于治疗各种疾病和失调的有用性，包括癌症，特别是利用Warburg效应的癌症。

  公开号：

  WO2022157548A1

文献信息

• Inhibitors of farnesyl protein transferase
  申请人：Bristol-Myers Squibb Company

  公开号：US06011029A1

  公开（公告）日：2000-01-04

  The present invention comprises benzodiazepine compounds having farnesyl transferase inhibitory activity.

  本发明涵盖具有法尼基转移酶抑制活性的苯二氮卓类化合物。
• [EN] THERAPEUTIC INHIBITORS OF THE REVERSE MODE OF ATP SYNTHASE<br/>[FR] INHIBITEURS THÉRAPEUTIQUES DU MODE INVERSE DE L'ATP SYNTHASE
  申请人：FORREST MICHAEL DAVID

  公开号：WO2018134265A1

  公开（公告）日：2018-07-26

  Compounds of the following formula, and pharmaceutically-acceptable salts, solvates, hydrates and prodrugs thereof, formula (A) are useful to preferentially inhibit the ATP-hydrolysing mode of ATP synthase, and are thereby useful for treating various diseases and disorders including cancer, particularly cancers that utilise the Warburg effect.

  以下化合物的公式，以及其药用可接受的盐、溶剂合物、水合物和前药，公式（A）可用于优先抑制ATP合成酶的ATP水解模式，并因此可用于治疗各种疾病和紊乱，包括癌症，特别是利用Warburg效应的癌症。
• Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
  申请人：——

  公开号：US20040009972A1

  公开（公告）日：2004-01-15

  Compounds having the formula (I), 1 are useful as inhibitors of mitochondrial F 1 F 0 ATP hydrolase, wherein R 1 , R 5 and R 7 are optional substituents, R 2 , R 3 and R 4 are hydrogen, alkyl, or substituted alkyl, or comprise a bond to R, T or Y; Z and Y are selected from C(═O), —CO 2 —, —SO 2 —, —CH 2 —, —CH 2 C(═O)—, and —C(═O)C(═O)—, or Z may be absent; R and T are CH 2 —, —C(═O)—, or —CH[(CH 2 ) p (Q)]—, wherein Q is NR 10 R 11 , OR 10 or CN and p is 0, 1 or 2; R 6 is alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl, heterocyclo, or heteroaryl; R 10 and R 11 are hydrogen, alkyl, or substituted alkyl; and r and t are 0 or 1.

  公式（I）的化合物可作为线粒体F1F0ATP水解酶的抑制剂，其中R1、R5和R7为可选取代基，R2、R3和R4为氢、烷基或取代烷基，或包括与R、T或Y之间的键；Z和Y从C(═O)、—CO2—、—SO2—、—CH2—、—CH2C(═O)—和—C(═O)C(═O)—中选择，或者Z可能不存在；R和T为CH2—、—C(═O)—或—CH[(CH2)p(Q)]—，其中Q为NR10R11、OR10或CN，p为0、1或2；R6为烷基、烯基、取代烷基、取代烯基、芳基、环烷基、杂环烷基或杂环芳基；R10和R11为氢、烷基或取代烷基；r和t为0或1。
• [EN] INHIBITORS OF ATP SYNTHASE - COSMETIC AND THERAPEUTIC USES<br/>[FR] INHIBITEURS D'UTILISATIONS COSMÉTIQUES ET THÉRAPEUTIQUES D'ATP SYNTHASE
  申请人：FORREST MICHAEL DAVID

  公开号：WO2022157548A1

  公开（公告）日：2022-07-28

  With supporting experimental data, this disclosure teaches that IF1 protein activity is a molecular determinant of lifespan, therein explaining why different species have different maximal lifespans, and it teaches a IF1 protein/fragment (or sequence variant thereof), or a fusion protein thereof, optionally a fusion protein comprising a Cell Penetrating Peptide (CPP) sequence, as an agent to slow/delay/reduce aging in a subject, optionally as a component of a cosmetic, optionally to treat an age-correlated disease/disorder. Moreover it teaches other inhibitors of F1F0 ATP hydrolysis, including small molecules, of a number of different scaffolds, for this purpose. Furthermore, with supporting experimental data, it teaches that compounds that slow the ATP-hydrolysing mode of ATP synthase are useful for treating various diseases and disorders, including cancer, particularly cancers that utilise the Warburg effect.

  本公开教导了IF1蛋白活性是寿命的分子决定因素，通过支持实验数据解释了不同物种具有不同最大寿命的原因。本公开教导了使用IF1蛋白/片段（或其序列变体）或其融合蛋白作为减缓/延迟/减少受试者衰老的药剂，可选作为化妆品组分，可选用于治疗与年龄相关的疾病/失调。此外，本公开还教导了其他F1F0 ATP水解抑制剂，包括多种不同支架的小分子，用于此目的。此外，通过支持实验数据，本公开还教导了减缓ATP合成酶的ATP水解模式的化合物对于治疗各种疾病和失调的有用性，包括癌症，特别是利用Warburg效应的癌症。
• Therapeutic Inhibitors of the Reverse Mode of ATP Synthase
  申请人：FORREST Michael David

  公开号：US20200247758A1

  公开（公告）日：2020-08-06

  Compounds of the following formula, and pharmaceutically-acceptable salts, solvates, hydrates and prodrugs thereof, formula (A) are useful to preferentially inhibit the ATP-hydrolysing mode of ATP synthase, and are thereby useful for treating various diseases and orders including cancer, particularly cancers that utilise the Warburg effect.